Mometasone/formoterol

Drug Profile

Mometasone/formoterol

Alternative Names: Dulera; Formoterol/mometasone; MF/F; MFF 258; MK-0887A; MK-08887A; MK-887A; Mometasone furoate/formoterol fumarate; SCH 418131; Zenhale

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novartis; Schering-Plough
  • Developer Merck & Co; Novartis
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnadienediols; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • No development reported Allergic asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Mar 2016 Phase-III clinical trials in Asthma (In children) in Latvia and Hungary (Inhalation) (EudraCT2009-010110-30)
  • 16 Oct 2012 Merck completes a phase III trial in Asthma in Vietnam (NCT01566149)
  • 24 Jul 2012 Merck completes enrolment in its phase III trial for Asthma in Vietnam (NCT01566149)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top